Phase II/III randomized trial of TCH346 in patients with ALS

R. Miller*, W. Bradley, M. Cudkowicz, J. Hubble, V. Meininger, H. Mitsumoto, D. Moore, H. Pohlmann, D. Sauer, V. Silani, M. Strong, M. Swash, E. Vernotica, Neil Cashman, Andrew Eisen, Charles Krieger, Angela Genge, Sanjay Kalra, John Turnbull, Lucette LacomblezWilliam Camu, Alain Destee, Albert Christian Ludolph, Reinhard Dengler, Thomas Meyer, Adriano Chio, L. H. Van Den Berg, M. De Visser, Francois Vingerhoets, Orla Hardiman, N. Leigh, Jeremy Shefner, William David, Michael Graves, Terry Heiman-Patterson, Hans Neville, Jeffrey Rosenfeld, Mark Bromberg, Andrea Corse, Andrew Waclawik, Erik Pioro, Robert Sufit, Stanley Appel, Robert Pascuzzi, John Kissel, Carlayne Jackson, Richard Barohn

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

100 Scopus citations


Dive into the research topics of 'Phase II/III randomized trial of TCH346 in patients with ALS'. Together they form a unique fingerprint.

Agricultural and Biological Sciences

Medicine and Dentistry


Biochemistry, Genetics and Molecular Biology